Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial
Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed to meet the primary endpoint of progression-free survival (PFS). The late-stage trial assessed the combination of NINLARO (ixazomib) with lenalidomide and dexamethasone in comparison to lenalidomide and dexamethasone plus placebo […]
DKd regiment FDA approval for multiple myeloma : Janssen Pharmaceutical Companies of Johnson & Johnson and Amgen have been granted an expanded approval from the US Food and Drug Administration (FDA) for the DKd regimen comprising the former’s DARZALEX (daratumumab) and the latter’s Kyprolis (carfilzomib) plus dexamethasone for the treatment of multiple myeloma. The approval […]
Continue reading …
The University of Oxford said that steroid dexamethasone has succeeded in reducing death in the ongoing RECOVERY trial in hospitalized patients with severe respiratory complications of COVID-19. The RECOVERY trial was launched in March 2020 as a randomized clinical trial to evaluate a range of potential treatments for coronavirus, including low-dose dexamethasone, which is a steroid […]
Continue reading …RECOVERY coronavirus trial : First patients enrolled in COVID-19 clinical trial by University of Oxford
March 26, 2020 No Comment
RECOVERY coronavirus trial : University of Oxford researchers in the UK have initiated a coronavirus clinical trial called the Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial. The RECOVERY clinical trial, which has enrolled the first patients, will test the effects of potential drug treatments for COVID-19 patients admitted to hospitals. The objective of the clinical […]
Continue reading …CANDOR clinical trial results : Amgen’s Kyprolis extends PFS in multiple myeloma patients
September 13, 2019 No Comment
CANDOR clinical trial results : Amgen said that a phase 3 study assessing Kyprolis (carfilzomib) in combination with dexamethasone and Johnson & Johnson’s Darzalex (daratumumab) (KdD) compared to Kyprolis and dexamethasone alone (Kd), called CANDOR, met its primary endpoint of progression-free survival (PFS) in multiple myeloma patients. The Amgen clinical trial featured 466 relapsed or […]
Continue reading …
The US Food and Drug Administration (FDA) has approved a weekly once dosing option for Amgen blood cancer drug Kyprolis (carfilzomib) in combination with dexamethasone (once-weekly Kd70) for patients having relapsed or refractory multiple myeloma. The prescribing information has been expanded to include a new weekly once dosing of 70 mg/m2 of KYPROLIS. Approval for […]
Continue reading …
Business News Today
- Boxlight acquires AV solutions provider Sahara Presentation System
- SSGT II acquires two self storage facilities near Tampa, Florida
- Preferred Apartment Communities to sell student housing portfolio to TREP
- Corbion, Total to build €200m PLA bioplastics plant in France
- iPipeline acquires Impact Financial Systems
- Nautilus Solar Energy acquires 17MW solar portfolio from Pine Gate Renewables
- Palladium Equity Partners acquires majority stake in Trachte USA from MPE Partners
- The Hilb Group acquires life and health agency Ganim Benefits in Connecticut
- La Brea Bakery to invest in automation processes at Van Nuys bakery
- REG begins construction on single wind turbine project in Minnesota
